At the end of the 20th century new peritoneal dial ysis (PD) solutions were introduced in hope of im proving quality of life and survival of patients treat ed with PD. A solution with glucose polymers (PG DS) was designed to enhance ultrafiltration over the long dwell for the better removal of excess wa ter; a solution containing amino acids (AA DS) was expected to affect protein malnutrition, and so lutions with neutral pH and low levels of glucose degradation products (GDP) were meant to pro tect the peritoneal membrane against the combi nation of low pH, high lactate levels and harmful effects of GDP. Regardless of specific indications for each solution, all are considered as more bio compatible comparing to standard high glucose and low pH solutions, buffered with lactate.
At the end of the 20th century new peritoneal dial ysis (PD) solutions were introduced in hope of im proving quality of life and survival of patients treat ed with PD. A solution with glucose polymers (PG DS) was designed to enhance ultrafiltration over the long dwell for the better removal of excess wa ter; a solution containing amino acids (AA DS) was expected to affect protein malnutrition, and so lutions with neutral pH and low levels of glucose degradation products (GDP) were meant to pro tect the peritoneal membrane against the combi nation of low pH, high lactate levels and harmful effects of GDP. Regardless of specific indications for each solution, all are considered as more bio compatible comparing to standard high glucose and low pH solutions, buffered with lactate.
Biocompatibility of PD solutions is related to their more physio logical pH, lower osmolarity, a decreased load of glucose and lower content of GDP as compared to standard solutions. A de creased load of glucose, despite meta bolic conse quences regarding multiple tissues and organs, contributes to reduced formation of Amadori albumin and advanced glycation end products (AGE) in the peritoneum.
1 Lower content of GDP protects against direct harmful effects of GDP 2, 3 and also leads to a reduction in AGE accumula tion in the peritoneum 4,5 because GDP enhance AGE formation.
More bio compatible PD solutions should pre vent or diminish changes in the peritoneal mem brane occurring in the course of PD. Normal peri toneal membrane becomes thicker due to fibro sis, neoangiogenesis and accumulation of AGE. On the other hand, mesothelial cell mass de creases and the area of mesothelial denudation in the European Automated Peritoneal Dialy sis Outcomes Study (EPOS), performed in func tionally anuric patients, peritoneal transport in creased after 2 years of examination, indepen dently on solutions administered for treatment, but patients treated with the PG DS for daytime exchange showed lower peritoneal permeability than patients who used only glucose solutions, al though patients using the PG DS showed signif icantly higher peritoneal permeability at the be ginning of the study. This prospective, but not randomized study shows that the PG DS slows development of peritoneal permeability, at least under circumstances in which this process may be more enhanced due to high glucose levels used to achieve appropriate ultrafiltration in anuric patients. 19 A short (8 week) prospective, randomized study did not show the effect of AA DS on perito neal permeability in the PD capacity (PDC) test.
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These data are compatible with results obtained by Li et al. 24 during an appropriate follow up, pub lished in 2003. However, the study by Li et al. 24 with 3 years' follow up demonstrated an increase in peritoneal permeability from 6 to 30 months of treatment with the AA DS, with higher values of MTAC of creatinine (but not urea) compared with results obtained for patients treated with standard solutions.
Solutions with neutral pH, likewise standard solutions, showed no effect on peritoneal perme ability in prospective, randomized studies lasting from 8 weeks to 2 years. [25] [26] [27] Preservation of mesothelial cell mass In patients treated with the PG DS a decrease in peritoneal mesothelial cell mass cannot be excluded because cancer antigen (CA) 125 levels in dialysate tended to decrease and CA 125 dialysate/plasma (D/P) was significantly lower after 2 years of treatment with the PG DS. However, there were no signifi cant differences between groups when the anal ysis of variance (ANOVA) was used in statisti cal analysis.
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The AA DS, which also has a more physio logical pH as compared to standard solutions, in a pro spective, randomized study the AA DS was asso ciated with an increase in the dialysate CA 125 level, suggesting successful remesothelialisation following damage due to the previous use of glu cose solutions. However, exposure to the AA DS was not more than 8 weeks.
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Administration of neutral pH/low GDP so lutions resulted in the higher level of CA 125 in dialysate. 5, 7, 25, 28, 29 It was shown with the use of lactate buffered solutions prepared in three or two compartment bags, with bicarbonate/lac tate (bic/lac) solutions and with bic buffered so lutions. This beneficial effect was observed up to 2 years of the study. A withdrawal of a more bio compatible solution resulted in a decrease in peritoneal mesothelial cell mass. There is no data comparing effects of various neutral pH so lutions in a single prospective study.
can be shown. Numerous in vitro, ex vivo and in vivo studies that addressed the issue of bio compatibility supported hopes related to the in troduction of new solutions. Benefits of more bio compatible solutions include improved mesothe lial cell proliferation and better preserved meso thelial cell mass, 6-8 an intact mesothelial cell lay er, 9,10 improvements in viability of mesothelial cells, neutrophils and macrophages, especially aug mented phagocytic activity, 5,11-14 less angiogenesis in the parietal peritoneum and a reduction in fi brosis in the mesentery (~50%) and in the pari etal peritoneum (~25%), 10 reduced bacterial sur vival 15 and less damage to cultured liver cells 16 . Benefits were shown especially with neutral pH solutions and the AA DS. Comparisons of the in fluence of PG DS and standard fluids on prolifer ation, morphology and secretory function of me sothelial cells provide various results. In some ex perimental studies a 7.5% PG DS substantially re strained the normal process of mesothelial cell re population and induced repair with the connective tissue. The harmful effects of PG DS were usually reported as smaller or comparable to those asso ciated with a 4.25% glucose solution. 17, 18 In studies evaluating effects of bio compatibility of peritoneal solutions, each new solution is an alyzed separately. In clinical practice only neu tral pH dialysis solutions can be exclusively used in the PD regimen, whereas the PG DS and AA DS are at present allowed only for 1 exchange daily. Thus, the clinical effects of the 2 latter so lutions are influenced by fluids used for the re maining daily exchanges, usually still performed with standard solutions. A question arises how all these more bio compatible dialysis solutions influence para meters important for treatment with PD, and how they influence the outcome measured in the so called hard end points. The an swer for this question 1 in results of prospective, randomized, long term clinical trials. Current ly available studies are focused on para meters of peritoneal transport as indictors of the time dependent increment in peritoneal permeabili ty, para meters of peritoneal membrane viability, indices of local and systemic chronic inflamma tory state, peritonitis rate, survival of patients and prolongation of PD treatment and evalua tion of usability to specific targets designed for each solution. The main results related to these key problems will be presented.
Influence on peritoneal transport Peritoneal trans port increases in the course of PD. It was also shown with the use of PG DS. 19, 20 However, in pa tients treated with cyclic continuous PD (CCPD), having still preserved residual renal function, peritoneal transport measured using the mass transfer area coefficient (MTAC) for urea, creati nine, uric acid and glucose, remained unchanged during 2 years followup and was not significant between the groups treated using the PG DS for daytime exchange and the group using glucose solution for daytime exchange. 21, 22 Moreover, accompanied by higher peritonitis rate in the stan dard group compared to the bic group. 36 In a 1 year randomized clinical study serum CRP levels even decreased when the solution with neutral pH and low GDP content in double chamber bags was used. Changes in serum CRP levels in this study were not significant in the standard group and peritonitis free survival was similar in the standard group and the group treated with neutral pH solutions. 29 As it was observed in the study by Montenegro et al., 36 lower peritonitis rate was also shown in pa tients treated for 1 year with a bic (25 mmol/l)/ lac (15 mmol/l) solution instead of a standard lac (40 mmol/l) solution in a prospective, random ized study. 26 Analysis of 121 cases of peritonitis, which occurred in the years 2002-2005 in 1 hospi tal in London, also revealed lower peritonitis rate (1 episode per 52.5 patient months) in patients treated with a bic (25 mmol/l)/lac (15 mmol/l) solution compared to peritonitis rate (1 episode per 26.9 patient months) in patients treated with standard lac solutions. 37 Solutions with neutral pH, but not containing higher amounts of bic, did not change significantly peritonitis rate. 29, 38 Treatment with the PG DS for 6 months in the prospective, randomized, controlled Mul ticentre Investigation of Icodextrin in (contin uous) Ambulatory Dialysis (MIDAS) did not in fluence peritonitis rate compared to standard solutions. 39 The Dextrin in Ambulatory Perito neal Dialysis in Amsterdam (DIANA) did not ob serve any significant difference in peritonitis rate in the 2 year study in patients treated with CCPD with standard solutions only or with the PG DS for daytime exchange. 22 Retrospective studies suggested low peritonitis rate in continuous am bulatory PD (CAPD) patients using the AA DS, 40 but a 3 year prospective study did not confirm this observation.
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Mortality rate During a 2 year treatment with the PG DS mortality rate was significantly lower in patients using the PG DS instead of glucose 1 for daytime exchange, but the DIANA Group con sidered this as a coincidence. 22 Mortality rate was identical in malnourished Chinese patients ei ther using or not using the AA DS for 3 years.
A Korean study, based on registry of over 2000 patients treated with PD, showed lower mortality rate in patients using lactate buffered, but neutral pH, low GDP solutions instead of standard lactate solutions. In a multivariate cyclooxygenase regres sion model, including age, diabetes and gender, the survival advantage of a more bio compatible solution persisted.
38 The number of deaths during a 3 year prospective, but not randomized study, was also lower when a bic (34 mmol/l) dialysis so lution with pH 7.4 and low GDP content was used and compared to standard solutions. 36 These re sults suggest that more physio logical pH and low content of GDP in dialysis solutions may contrib ute to prolongation of patient life time, howev er, prospective, randomized studies have to con firm these observations.
secretory function of the peritoneal membrane
Parameters of secretory function of the perito neal membrane, as shown for the aminotermi nal propeptide of type III procollagen (PIIINP), did not change during 2 years of PG DS admin istration for daytime exchange in patients with preserved residual renal function treated with CCPD. 21, 22 These results were not different from those shown during the treatment with glucose solutions alone. The administration of a neutral pH/low GDP solution for 2 years resulted in an in crease in PIIINP in dialysate. 7, 25 These results were inter preted by authors as indicating a better func tion of peritoneal tissue. 25 However, in cultured mesothelial cells secretion of PIIINP was great er with less bio compatible solutions, and was related to higher glucose levels and higher con tent of GDP in the solution. 30 These data indicate an unsolved inter pretation difficulties by chang es in the examined peritoneal markers.
Inflammatory state and peritonitis rate Patients treated with the PG DS or AA DS showed an in crease in the inter leukin 6 (IL 6) level in di alysate. 23, 31 It is discussed again whether such an increase represents enhanced chronic inflam mation in the peritoneum, or it is a sign of less cellular inhibition or better preservation of cy tokine release during glucose free solutions. On the other hand, in 2 prospective, randomized studies 5,32 a bic (25 mmol/l)/lac (15 mmol/l) solu tion used instead of an acidic lac (40 mmol/l) so lution led to a decrease in IL 6 levels in dialysate. With a standard lac solution IL 6 levels increased in dialysate between the 1st and 5th months of the study whereas with a bic (25 mmol/l)/ lac (15 mmol/l) solution IL 6 levels decreased during 1 month and the lower IL 6 level was ob served to the analysis performed after 5 months of treatment. 5 However, administration of a bic (25 mmol/l)/lac (15 mmol/l) solution to patients receiving the PG DS and AA DS did not prevent an increase in the IL 6 level in dialysate. 31 In prospective, randomized studies patients receiving the PG DS for 8 weeks showed an in crease in serum C reactive protein (CRP). 23 How ever, in 2003 bacterial peptidoglycan was discov ered in the PG DS and, at present, only solutions with the peptidoglycan level lower than 10 ng/ml are allowed to be used in patients. 33, 34 It cannot be excluded that even studies published in 2005 could be performed using solutions with uncon trolled, high content of peptidoglycan. 35 The AA DS, administered for 3 years in mal nourished Chinese patients, did not cause an in crease in serum CRP, which was not significant ly different from CRP in patients using a stan dard solution.
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During the 3 year treatment with a bic dial ysis solution (34 mmol/l) in a prospective, but not randomized study, serum CRP levels did not change significantly. Patients using standard so lutions showed an increase in serum CRP levels during this 3 year follow up, but the change was albumin, bic, lipid profile, glucose, glycated hemo globin, as compared to respective results obtained for patients treated with standard solutions. Peri toneal transport, evaluated using the (D/P) ratio of creatinine and the ratio of dialysate glucose to baseline dialysate glucose (D/D 0 ) in the peri toneal equilibration test, was however signifi cantly higher with the PD regimen based on new solutions. On the other hand, mesothelial cell mass expressed by dialysate CA 125 levels de creased less after initiation of CAPD with new solutions and remained higher during the en tire study period. 43 suMMARy Current evidence provides support for using bio compatible solutions that have been designed to meet specific clinical needs (PG DS for enhancement of ultrafiltration in long dwells, AA DS for an improvement in or maintenance of protein nutrition, neutral solutions for correc tion of meta bolic acidosis and in cases of low tol erance of acidic solutions). A common use of neu tral pH/low GDP solutions for PD instead of stan dard lac buffered solutions is reasonable because there is evidence based on prospective, random ized studies showing better preservation of peri toneal cell mass, less pronounced systemic inflam mation and lower peritonitis rate of patients us ing these solutions. Long term (over 3 years) pro spective, randomized studies are needed to eluci date the issue as to whether more bio compatible PD solutions may prolong patient survival on PD treatment. Effects related to specific targets of peritoneal dialysis solutions Results of prospective studies confirm beneficial effects of the PG DS on ultra filtration for at least 0.5-2 years in nighttime ex changes in CAPD patients 42 and in daytime ex changes in CCPD patients. 22 Improved clinical para meters (stable body mass, less risk of edema) were also reported for at least 1 year by the Ico dextrin Study Group. 43 Prospective, randomized studies confirmed the expected influence of AA DS on the improve ment in or maintenance of nutritional status in malnourished PD patients, especially women, as shown here for lean body mass and body mass index. Treatment of malnourished patients with standard solutions for 3 years caused further de terioration of nutritional para meters. In patients treated with the AA DS an improvement in nu trition was accompanied by a decrease in serum triglyceride levels. 24 The clinical benefits of PD solutions with neu tral pH include correction of uremic acidosis in auto mated peritoneal dialysis 37,44 and CAPD patients [26] [27] [28] 37, 38, 45 as well as relief from inflow pain/discomfort.
REfEREnCEs Peritoneal dialysis technique survival
Clinical data indicate that the PG DS extends duration of CAPD treatment, 41 but there are no prospec tive, randomized studies to support these ob servations.
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side effects Treatment with more bio compatible solutions have also some side effects. The main clinical disadvantages of PG DS include sterile peritonitis (pseudoperitonitis), 34 skin reactions,
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a decreased serum sodium level with an increased osmolal gap 22 and increased serum levels of poly glucose meta bolites. 22, 42 The clinical disadvantages of AA DS include in creased generation of urea and uric acid, elevat ed plasma homo cysteine levels, gastrointestinal symptoms and decreased serum bic levels. 24, 47 The clinical disadvantages of dialysis solu tions with physio logical pH occur very seldom and include meta bolic alkalosis, occasionally ob served with solutions containing higher bic lev els (39 mmol/l).
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Combined effects of the PG -ds, AA -ds and neutral pH/low GdP solution Trials designed to show the advantages of PG DS, AA DS combined with those of neutral solutions have been pub lished.
43, 49 Treatment of new CAPD patients with the AA DS for 1 exchange, the PG DS for 1 ex change and neutral solutions for 2 remaining ex changes daily for 30 weeks did not result in sig nificant differences in dialysis efficiency, ultrafil tration, body weight, blood pressure, urine vol ume and laboratory blood tests, including hemo globin, sodium, potassium, calcium, phosphorus,
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Biozgodne płyny do dializy otrzewnowej: czy rzeczywiście poprawiają rokowanie?* Alicja E. Grzegorzewska 
sTREszCzEnIE
Wyniki licznych badań potwierdziły korzystne działanie płynu do dializy otrzewnowej zawierającego polimery glukozy (polyglucose dialysis solution -PG-DS), płynu zawierającego aminokwasy (amino acid dialysis solution -AA-DS) oraz płynów buforowanych wodorowęglanem (bicarbonate -bic) lub bic z dodatkiem mleczanów (bicarbonate/lactate -bic/lac) na wybrane składowe bio zgodności otrzewnowej lub kliniczne para metry chorych leczonych dializą otrzewnową (peritoneal dialysis -PD). Opisano także nieliczne objawy uboczne. Nasuwa się pytanie, czy wymienione płyny wpływają na rokowanie w PD. Lepszą kontrolę stanu nawodnienia chorych leczonych PD, związaną ze stosowaniem PG-DS, wykazano w badaniu z randomizacją, prowadzonym metodą podwójnie ślepej próby. Chorzy leczeni cykliczną PD z zastosowaniem PG-DS nie wykazywali zmian w kinetyce związków rozpuszczonych w wodzie, a wskaźniki żywotności błony otrzewnowej pozostały u nich niezmienione. Stosowanie PG-DS u chorych z bezmoczem leczonych auto matyczną PD wiązało się z mniejszym uszkodzeniem czynności i błony otrzewnowej. Prospektywne, randomizowane, kontrolowane badanie skutków AA-DS u niedożywionych chorych leczonych PD nie wykazało istotnego wpływu na długo ść życia chorych, częstość hospitalizacji, stężenie białka C-reaktywnego, całkowity wskaźnik adekwatności dializy mocznika, ultrafiltrację i liczbę chorych, którzy nie ukończyli badań, ale stan odżywienia poprawił się lub pozostał niezmieniony. Poprawę równo wagi kwasowo-zasadowej wykazano u chorych leczonych auto matyczną PD lub ciągłą PD z użyciem płynów buforowanych bic. Badanie oparte na danych z rejestru pacjentów sugerowało dłuższe przeżycie chorych leczonych płynem o obojętnym pH z małą zawartością produktów degradacji glukozy, ale nie było różnic w przetrwaniu techniki dializacyjnej, długo ści okresu czasu wolnego od zapalenia otrzewnej i częstości zapaleń otrzewnej. Jednakże wykazywano także zmniejszoną częstość zapaleń otrzewnej podczas stosowania płynu bic/lac. Aktualne koncepcje, dotyczące płynów do PD, obejmują próby stosowania płynów, które łączą korzyści PG-DS, AA-DS i płynów buforowanych bic. Szeroko zakrojone badania powinny być kontynuowane w celu poprawy bio zgodności płynów do PD i ustalenia ich wpływu na rokowanie kliniczne.
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